US 12,102,730 B2
Graphene-based nanofibers for skeletal muscle tissue regeneration
Nikoo Saveh Shemshaki, Farmington, CT (US); and Cato Laurencin, Farmington, CT (US)
Assigned to University of Connecticut, Farmington, CT (US)
Filed by University of Connecticut, Farmington, CT (US)
Filed on Jun. 18, 2021, as Appl. No. 17/352,189.
Claims priority of provisional application 63/041,594, filed on Jun. 19, 2020.
Prior Publication US 2021/0402054 A1, Dec. 30, 2021
Int. Cl. A61L 27/00 (2006.01); A61L 27/08 (2006.01); A61L 27/18 (2006.01); A61L 27/22 (2006.01); A61L 27/24 (2006.01); A61L 27/50 (2006.01)
CPC A61L 27/08 (2013.01) [A61L 27/18 (2013.01); A61L 27/222 (2013.01); A61L 27/24 (2013.01); A61L 27/50 (2013.01); A61L 2400/12 (2013.01); A61L 2430/30 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A scaffold comprising nanofibers, wherein the nanofibers comprise a mixture of graphene nanoplatelets and a biocompatible polymer,
wherein the biocompatible polymer is selected form the group consisting of collagen, gelatin, chitosan, hyaluronic acid (HA), silk fibroin, polylactide (PLA), polyurethane (PU), poly(ε-caprolactone) (PCL), poly(DL-lactide) (PDLLA), poly(ether ester) based on poly(ethylene oxide) (PEE based on PEO), polybutylene terephthalate (PBT), polyglycolide (PGA), poly(L-lactide-co-glycolide) (PLGA), poly(lactic acid-glycolic acid) (PLAGA), poly(ethylene-co-vinylacetate) (PEVA), poly(L-lactic acid (PLLA), and poly(L-lactide-co-ε-caprolactone) (PLLA-CL);
wherein the nanofibers comprise an average diameter of about 400 nm to about 1200 nm; and
wherein the graphene nanoplatelets comprise from about 0.5 wt % to about 2 wt % of the scaffold.